Related Experiment Videos
Tardive dyskinesia in elderly patients: an update
1Department of Psychiatry, Brown University, and Rhode Island Hospital, Providence, Rhode Island 02903, USA. rjgoldberg@lifespan.org
Journal of the American Medical Directors Association
|June 17, 2003
Summary
Tardive dyskinesia (TD) is a serious side effect of antipsychotic medications, especially in older adults. Novel antipsychotics may offer a safer alternative for managing these conditions in the elderly.
Area of Science:
- Neuroscience
- Geriatric Medicine
- Psychiatry
Background:
- Antipsychotic medications are crucial for treating schizophrenia and severe behavioral disorders.
- Extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) are significant side effects limiting antipsychotic use.
- Older age is a strong risk factor for developing TD.
Purpose of the Study:
- To review the relationship between aging and TD.
- To discuss the treatment of TD in elderly patients.
- To explore the role of novel antipsychotics in mitigating TD risk in the elderly.
Main Methods:
- Literature review focusing on TD, aging, and antipsychotic treatments.
- Analysis of clinical trial data regarding novel antipsychotics in elderly populations.
- Synthesis of current understanding of risk factors and management strategies for TD in older adults.
Main Results:
- Older age significantly increases the risk of developing TD.
- Novel antipsychotics demonstrate a reduced risk of EPS and TD compared to older agents.
- Emerging data suggest efficacy and safety of novel antipsychotics in elderly patients, though more research is needed.
Conclusions:
- TD remains a critical concern in elderly patients treated with antipsychotics.
- Novel antipsychotics represent a promising advancement for reducing TD incidence in this population.
- Further research is essential to fully understand the long-term safety and efficacy of novel antipsychotics in geriatric populations.